Overview

Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
Phase II study in patient with advanced Soft Tissue Sarcoma (STS) patients who have already received or are not suitable, for a doxorubicin-based treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Italian Sarcoma Group
Collaborators:
AstraZeneca
PharmaMar
Treatments:
Olaparib
Trabectedin